Delcath Systems, Inc. is a pioneering interventional oncology company headquartered in New York, specializing in innovative treatment solutions for both primary and metastatic liver cancers in the U.S. and Europe. Utilizing its proprietary technologies, Delcath focuses on direct delivery of cancer therapies to the liver, ensuring enhanced efficacy while reducing systemic side effects. With a robust clinical pipeline and a strategic vision for market expansion, the company aims to address critical unmet needs in oncology, thereby advancing patient care and improving therapeutic outcomes. Show more

Location: 566 QUEENSBURY AVENUE, NEW YORK, NY, UNITED STATES, 12804, New York, NY, 12804, USA | Website: https://www.delcath.com | Industry: MEDICAL DEVICES | Sector: HEALTHCARE

Market Cap

350M

52 Wk Range

$8.12 - $18.23

Previous Close

$9.91

Open

$9.84

Volume

401,087

Day Range

$9.75 - $9.97

Enterprise Value

255.9M

Cash

41.81M

Avg Qtr Burn

N/A

Insider Ownership

2.73%

Institutional Own.

52.70%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Liver Dominant metastatic Ocular Melanoma, Metastatic Uveal Melanoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HEPZATO™ Details Liver-Dominant Metastatic Breast Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HEPZATO™ Details Metastatic colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CHEMOSAT® Details Uveal melanoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details Intrahepatic cholangiocarcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.